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1. Introduction 
Primary focal and segmental glomerulosclerosis (FSGS) is the most frequently acquired 
disease leading to end stage renal disease (ESRD) in children (NAPRTCS 2004, annual 
report)1-6. The recurrence of FSGS after kidney transplantation is frequent (20-40%) and is 
associated with poor graft survival7-13. The pathophysiology of primary FSGS remains 
uncertain, but secretion of a circulating factor is suspected to play a key role in excessive 
glomerular permeability. Excepted for the recurrence of FSGS with a previous allograft, this 
event is almost unpredictable and characterized by early nephrotic range proteinuria. Some 
studies have identified risk factors for recurrent FSGS in children, including rapid 
progression to ESRD, young age of onset of FSGS and, of course loss of a previous graft 
from recurrent disease but none of these studies can clearly separate the patients who will or 
will not be affected by recurrence. The treatment of recurrence remains controversial, and 
most reports relate to use of plasma exchange (PE) in uncontrolled trials with relatively 
small groups of patients and conflicting results. PE and protein immunoadsorption can 
markedly reduce urinary protein excretion and induce complete remission in some cases, 
but they usually fail to achieve sustained remission14-16. Steroids and cyclosporine are also 
associated with inconstant remission and act through different ways. More recent 
therapeutic approach seems promising and need to be evaluated in large trials. This review 
summarizes the various therapeutic approaches to FSGS recurrence. 
2. Pathogenesis of FSGS recurrence 
To better understand the therapeutic approaches to FSGS recurrence, we might briefly 
comment on its pathogenesis. The pathophysiology of this disease remains largely unclear 
and is thought to involve at least three types of cells (T-cells, B-cells and podocyte) and a 
circulating factor. In 1974, to explain what would later be called idiopathic nephrotic 
syndrome (INS), Shalhoub proposed the hypothesis (Shalhoub hypothesis) of T-cell 
dysfunction resulting in the secretion of “circulating chemical mediator toxic to an 
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immunologically innocent glomerular basement membrane”17. Although knowledge of the 
pathogenesis of this disease has improved in recent years, novel therapeutics have not 
ameliorated the rate of its recurrence. T-cell disorder is still suspected based on much 
evidence for Th2 cytokine bias in INS. Sahali et al. were the first to report that T-cells from 
INS patients are driven toward a Th2 phenotype18. By screening a cDNA library from T-cells 
of patients with relapsing INS they found that overexpression of truncated c-maf–inducing 
protein (Tc-mip) induced c-maf, transactivated the IL-4 gene, and downregulated IFN 
expression, characteristic of Th2 commitment19. These data were also supported by the 
observation of increased expression of cytoplasmic IL-13 mRNA in T-cells from patients 
with relapsing INS as compared to those in remission and control patients20. Furthermore, 
overexpression of IL-13 in Wistar rats led to minimal change disease confirming the 
potential role for Th2 predominance in pathophysiology of INS21. More recently, the 
expression level of soluble ST2 protein (sST2), a marker of Th2 cells that is predicted to be 
regulated by c-maf, was investigated in a population of patient with FSGS recurrence after 
transplantation22. The level of sST2 were increased after transplantation in patients with 
recurrence compared to the control group; however this protein was unable to induce 
podocyte injury in vitro suggesting that it could be a marker of recurrence but might not be 
implicated in the pathogenesis of recurrence. Using a humanized mouse model, Sellier-
Leclerc et al showed that CD34+ stem cells, unlike CD34- peripheral blood mononuclear cells, 
from patients with INS induced albuminuria, suggesting the involvement of immature 
differentiating cells rather than mature peripheral T-cells in the pathogenesis of the 
disease23. Thus, there is evidence for T-cell dysfunction in INS, but treatments targeting T-
cells (calcineurin inhibitors, anti-CD3 or anti-CD52) are not completely effective in 
preventing or treating FSGS recurrence. Furthermore, there is recent evidence for B-cell 
participation from a report of remission obtained with rituximab (anti-CD20)24. Indeed, it is 
accepted that primary FSGS is the consequence of a complex interaction between T- and B-
cells leading to the secretion of a circulating factor targeting podocyte. The presence of a 
circulating vascular permeability factor implicated in the physiopathology of this disease is 
highlighted by (i) the early recurrence of nephrotic syndrome after transplantation25, (ii) the 
fact that serum from patients with recurrent FSGS infused in rats can induce albuminuria26, 
(iii) the occurrence of a transient nephrotic syndrome in newborn infants of women with 
FSGS27, and (iv) the efficiency of plasma exchange and/or immunoadsorption at inducing 
remission15. The biochemical characteristics of this factor, however, are still unknown. Its 
molecular weight is suspected to be between 30-100 kDa, and Dantal et al. suggested that it 
could be a part of a complex with immunoglobulins28. Recently, Savin et al. found that this 
circulating factor had a high affinity for galactose and that all its activity was eliminated by 
galactose affinity columns29. The third player in this complex disease is the podocyte. 
Podocytes are a post-mitotic cell, arrested in G2/M phase of the cell cycle, and do not 
proliferate. It has been postulated that the circulating factor and/or immune cells directly 
interact with podocytes, and could induce the redistribution of the protein of the slit 
diaphragm, the loss of nephrin and/or podocin and the effacement of the foot processes, a 
hallmark of podocyte injury30. It has been suggested that foot processes effacement, if 
reversed, can lead to the restoration of glomerular architecture, which is typically observed 
in steroid-sensitive minimal change disease. The failure of repair mechanisms promotes 
podocyte detachment, apoptosis, podocyte depletion and FSGS. A special situation is 
collapsing glomerulopathy, a specific variant of FSGS. Findings in human suggest that 
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podocytes may undergo a proliferative state and phenotypic changes in collapsing 
glomerulopathy31, 32. Importantly, evidence suggests that, in addition to podocytes, parietal 
epithelial cells also participate in the collapsing glomerulopathy phenotype33. Recently, 
Reiser et al. described the expression of the co-stimulatory molecule B7.1 on podocytes34. 
The significance of the presence of this molecule is not clearly understood and remains 
speculative.  
3. Treatment of FSGS recurrence 
Despite the introduction of new immunosuppressive regimens, discovery of cyclosporine, 
and use of induction therapies, the incidence of FSGS recurrence has remained unchanged35-
37. In the case of recurrence treatments are not standardized, and show inconstant results. 
Most reports concern children and involve a small number of patients15, 38-46. Cyclosporine 
(CsA) has shown some degree of efficacy in pediatric subjects43, 44. Indeed, intravenous CsA 
after FSGS recurrence was associated with a drastic decrease of proteinuria in 82% of 
patients, although PE was added in some resistant cases43. A few reports have studied the 
use of tacrolimus to prevent or to treat recurrence. The results of these studies are almost 
inconstant47, 48. Due to the presence of a circulating permeability factor, most transplant 
teams test the efficacy of PE, which substitutes the plasma of the patient with either plasma 
from healthy pooled donors, albumin or colloidal substance. This treatment usually induces 
a reduction in proteinuria and, in some cases complete remission.  Determining when to 
begin PEs, their frequency, duration and optimal stop time are challenging to determine, 
and most remissions are PE-dependant. Others supporting approaches have also been used, 
such as anti-human immunoglobulin affinity immunoadsorption and tryptophan 
immunoadsorption28, 49. 
We recently conducted a non-randomized pilot trial of intensive and prolonged multiple 
treatment of FSGS recurrence in adult kidney transplant recipients50. As this complex 
disease involves systemic immune dysregulation targeting podocyte, we used a strategy of 
concomitant high dose steroids and intravenous CsA not only for their immunosuppressive 
properties, but also for their podocyte cytoskeleton stabilization properties, and with PE 
sessions. Glucocorticoid receptors are present on podocytes, have anti apoptotic properties 
in vitro 51 and could stabilize the actin cytoskeleton52. CsA acts directly on podocytes by 
blocking calcineurin-mediated dephosphorylation of synaptopodin and stabilizes actin 
cytoskeleton53. We decided to add PE sessions based on the presence of the circulating factor 
and an increased five-year allograft survival rate in our own experience. Indeed, from 
January 1994 to December 2004, we observed that the five-year allograft survival rate was 
55% in cases of FSGS recurrence (R group), compared to 93% in cases without recurrence 
(NR group) (p<0.01). In the R group, patients who benefited from PE had an increased five-
year allograft survival rate (91%) similar to the NR group, whereas patients not treated with 
PE had a five-year allograft survival rate of only 40% (p<0.01).  
The details of our therapeutic strategy consisted of high dose of oral steroids (1 mg/kg/d) 
for the first 4 weeks followed by tapering according to the following sequence: 0.75 
mg/kg/d for 2 weeks, 0.5 mg/kg/d for two weeks, 0.25 mg/kg/d for two weeks and 0.2 
mg/kg/d or a maximal daily dose of 10 mg thereafter. We used 14 days of intravenous CsA 
(2 mg/kg, targeting a blood level between 200 and 400 ng/ml) followed by oral treatment, 
targeting C2 levels between 1,200 and 1,400 ng/ml. PEs were performed with 5% albumin 
replacement (three sessions per week for three weeks, followed by two sessions per week 
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for three weeks, one session per week until month 3, two sessions per month until month 5, 
and once per month until month 9). Once remission was obtained, an angiotensin-
converting enzyme inhibitor and/or angiotensin receptor blocker were introduced. Rescue 
with rituximab therapy was anticipated in case of failure. The primary endpoint was the 
induction of a complete (<0.3 g per 24H) and sustained (>12 months) remission of 
proteinuria. The treatment was started after 3 days of nephrotic-range proteinuria without 
spontaneous improvement. Of 286 kidney transplant procedures performed between 
September 2005 and March 2007 at our institution, 18 were performed in patients with 
primary FSGS.  After transplantation these individuals were carefully monitored for 
proteinuria and ten (56%, eight men, two women) exhibited recurrence. The mean age at the 
onset of primary FSGS in native kidneys was 19.1 ± 14.8 years, leading to ESRD 8.1 ± 8.6 
years later. The mean duration of hemodialysis was 2.8 ± 2.4 years. For nine of the patients, 
this transplant was their first; the remaining patient had received two previous kidney 
transplants, both of which had been quickly lost due to recurrence. After kidney 
transplantation, all patients received an immunosuppressive regimen including prednisone, 
mycophenolate mofetil, oral CsA (n=10) or tacrolimus (n=8), along with an induction of 
either basiliximab (n=12) or antithymocyte globulin (Thymoglobulin®, n=6). Proteinuria 
occurred immediately after transplantation in six patients (60%) and early post-transplant in 
the remaining four (range 4-55 days). Recurrence was associated with massive proteinuria 
(mean 12 ± 11 g/day). We began PE within the first ten days of diagnosis in all patients, 
while high-dose steroids and intravenous CsA were initiated at the time of diagnosis. 
Complete proteinuria remission was achieved in all patients at a mean of 22.9 ± 6.6 days 
post-diagnosis. Three months after diagnosis, all patients were still in complete remission 
(mean proteinuria 0.16 ± 0.09 g/day) and all but one patient remained in remission at one 
year (mean proteinuria 0.19 ± 0.29 g/d).  In the nine patients with complete remission, PE 
was tapered gradually until month 9 and then stopped. During early follow-up (mean 15.8 ± 
3.3 months), none of these nine patients relapsed. At one year post-transplant, mean serum 
creatinine was 121 ± 29µmol/l and the measured iohexol glomerular filtration rate was 68.5 
± 18ml/min. The patient who failed to obtain sustained remission of proteinuria was the 
individual who had undergone a third kidney transplant. In this patient, proteinuria 
recurred when the frequency of PE was tapered to less than once per week. Rituximab 
infusion was attempted, and after two doses circulating B-cells were completely depleted 
(CD19 < 1/mm3).  Proteinuria was maintained in the range 1-2 g/day with PE administered 
twice per month.  
Long term follow-up (34.2 ± 6.7 months) of this cohort revealed that all these patients were 
still in complete remission with a mean proteinuria level of 0.11 ± 0.07 g/day and a mean 
serum creatinine of 122.6 ± 18 µmol/l. The patient in partial remission went into complete 
remission by maintaining PE (two times per month). During the follow-up, none of these 
patients developed diabetes, cancer or severe infectious disease. Indeed, long-term follow-
up of our cohort revealed that intensive treatment of FSGS induces not only an excellent 
short term response but also a complete and sustained remission of proteinuria without 
significant immunosuppressive regimen-associated adverse effects. 
We then considered whether the treatment administered in case of FSGS recurrence 
impacted the pathological features of FSGS during the post-transplant course. To address 
this question, we retrospectively studied 77 patients from January 1984 to December 2007, 
including both children and adults with primary FSGS who underwent renal 
transplantation54. Of these, 42 patients experienced a recurrence of nephrotic-range 
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proteinuria. After kidney transplantation, recurrence of proteinuria occurred immediately in 
32 of the 42 cases (children, n = 28; adults, n = 4), early in 9 of the 42 cases (children, n = 4; 
adults, n = 5) and late in 1 of the 42 case (adult, n = 1). Briefly, at time of recurrence, day 6 to 
day 60 days after transplantation, no glomerular lesion was observed in 32 of 33 biopsies 
and we considered them as minimal change disease. Only one patient had already 
developed a FSGS lesion. At month 3, FSGS lesions were observed in 11 of 39 cases, and at 
month 12, they were observed in 14 of 37 cases. Interestingly, 17 of the 42 patients went into 
complete and sustained remission, and none of them developed FSGS. On the other hand, 
patients who never achieved complete and sustained remission developed FSGS lesions. 
These data suggest continuing intensive treatments if no FSGS lesion are observed on 
transplant biopsies. 
4. Other available treatments 
4.1 Preemptive PE 
A few studies of preemptive PE have been reported that show inconstant efficacy and lack a 
control group. In 2005, Gohh et al conducted a prospective study to test whether pre-
transplant PE could prevent recurrence of primary FSGS in high risk patients55. A high risk 
of FSGS recurrence was defined by a rapid evolution toward ESRD (n= 4) or prior allograft 
loss due to recurrence (n= 6). Patients were subjected to a course of eight PE sessions over 2 
weeks in the immediate peri-operative period. Recipients of living donor kidneys initiated 
PE treatments 1 week before transplantation and completed their course at the end of the 
first post-operative week. Recipients of cadaver kidneys underwent an initial PE within 24 h 
of implantation. FSGS recurred in 3 of 10 patients, each of whom had lost prior transplants 
to recurrent FSGS. Two of these progressed to ESRD and the third had significant renal 
dysfunction. The authors conclude that PE may decrease incidence of FSGS recurrence in 
this particular population (rate of recurrence expected without PE: 60%). This therapeutic 
approach is difficult to organize in case of deceased donors, which is the major group of 
donors in many countries including our own. Furthermore, PE session before or soon after 
transplantation, may increase the risk of major bleeding despite the finding that no adverse 
event were reported in the previous study. This approach would also lead to excessive 
treatment in 50% of patients. 
4.2 Rituximab 
In 2006, Pescovitz et al reported complete remission after infusion of rituximab in a young 
transplant recipient24. After kidney transplantation this child rapidly developed FSGS 
recurrence resistant to PE and CsA and at month 5 developed a post-transplantation 
lymphoproliferative disease (PTLD). After six infusions of rituximab to treat the PTLD, 
proteinuria disappeared suggesting a possible interaction between B- and T-cells that leads 
to the secretion of permeability factor. Since that report, many transplant teams have tested 
the ability of rituximab to treat FSGS recurrence with inconstant results56-59. In fact, 
rituximab seems to induce remission in about 50% of cases, but some questions remain 
unsolved. When should the infusion begin: as an induction therapy or at time of recurrence? 
How many infusions should be administered, given that depletion of circulating B-cells 
does not always correlate with lymphoid organ depletion60? What are the long term side 
effects of this treatment? To date, no consensus has emerged, and double-blind studies are 
needed to determine the therapeutic potential of rituximab. 
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The co-stimulation molecule B7.1 is normally expressed on antigen presenting cells and B-cells. 
Recently, Reiser et al found that B7.1 is also expressed on podocyte and could be upregulated 
in many proteinuric states34. Again, the significance of the presence of this molecule is not 
clearly understood and remains speculative. To date, no published studies have evaluated 
blockade of this co-stimulation pathway for the treatment of FSGS recurrence. 
4.4 Anti-TNF 
TNF mRNA was found to be upregulated in macrophages preceding the development of 
nephrotic syndrome in Buffalo/Mna rats61. Furthermore, a high level of TNF mRNA was 
detected in mononuclear cells from patients with FSGS62. Anti-TNF therapy was recently 
tested in a child with resistant FSGS recurrence63 and induced transient complete remission, 
but every relapse was sensitive to anti-TNF infusion. 
4.5 Retinoic acid, Roscovitine and cyclin dependant kinase inhibitor 
Collapsing glomerulopathy recurrence is a situation in which podocytes can proliferate. 
Using in vitro and in vivo mouse models, retinoic acids were found to be efficient at reducing 
podocyte proliferation and proteinuria64. An on going study is evaluating treatment of 
collapsing glomerulopathy in native kidneys using retinoic acid (NCT00098020). 
4.6 Galactose 
Recently, Savin et al. found that the circulating factor has a high affinity for galactose, and 
that its activity can be removed by use of galactose affinity columns29. This group and one 
another reported a significant reduction in proteinuria following administration of galactose 
along with others therapeutics29, 65. A clinical trial (NCT00098020) is recruiting patients to 
treat primary FSGS in native kidney with galactose. Galactose has an excellent safety profile 
and could be an interesting therapeutic candidate. 
5. Conclusion 
Primary FSGS remains mysterious with a poorly understood pathogenesis. Recurrence is 
still frequent and associated with a poor allograft prognosis. We clearly must increase our 
knowledge of the pathogenesis of this disease to better identify specific risk factors for 
recurrence and design more specific therapeutic strategies. Our pilot study, although limited 
by a small population size, provides very encouraging results. Combined and intensive 
therapy showed a markedly beneficial effect on early proteinuria recurrence in this cohort of 
adult kidney transplant recipients. These preliminary results require confirmation on a 
larger scale with extensive follow-up. We have also described patients who went into 
complete and sustained remission and did not develop FSGS; patients who never achieved 
complete and sustained remission developed FSGS lesions. New therapeutics such as 
rituximab, anti-TNF galactose and retinoic acid should be evaluated in randomized 
double-blind studies. A better understanding of the molecular function of podocytes give 
hope that new therapeutics will be available in the next future. 
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